Thaver

Due Diligence For Companies: A Practical Guide for Life Sciences Investors

You found a promising biotech. The science checks out. The founders are sharp. But here's the question investors forget to ask early enough: will anyone actually buy this?
That's where due diligence for companies in life sciences gets tricky. A drug or device can be brilliant in the lab and still flop in the market. Clinical data tells you if something works. It doesn't tell you if hospitals will adopt it, or if a bigger competitor is already three steps ahead.

Writen by Nandy Thaver

12 October 2026

Why commercial due diligence matters more here

Life sciences deals move slowly and cost a lot. So when investors finally get to the commercial question, they can't afford guesswork. Due diligence for companies at this stage needs to answer three things: is the market real, who else is chasing it, and can this team sell into it?

Miss any of these, and you end up funding a product nobody buys, no matter how good the underlying science is.

What good commercial due diligence covers

A solid review usually looks at:

  • Market size and demand. Not the headline TAM slide. The real, addressable, paying market.
  • Competitive landscape. Who's already there, what they charge, and what gap actually exists.
  • Pricing and reimbursement. Especially critical in healthcare, where payer decisions can make or break revenue.
  • Go-to-market readiness. Does the company have a plan, or just a pitch deck?
  • Commercial risk. What could quietly derail growth after the check clears.

This is where a firm like Thaver comes in. Thaver works with investors and life sciences companies to test market validity, map out the competition, and flag commercial risks before capital moves. Their Market Fit & Due Diligence service fills this gap, giving investors a clearer read on whether an opportunity holds up beyond the science.

Where a fractional chief commercial officer fits in

Here's something founders often overlook. Great R&D teams rarely have great commercial instincts, and that's fine, until it isn't. Bringing in a fractional chief commercial officer during diligence, or right after the deal closes, gives a company senior commercial leadership without the cost of a full-time hire.

Such a person can pressure-test the go-to-market plan, build the early sales pipeline, and give investors confidence that someone experienced is steering commercial execution. Thaver's Fractional CXO service does exactly this, placing experienced commercial leaders into startups and scaling companies that need direction fast.

The bottom line

Good science needs a market to land in. Due diligence for companies in this sector isn't a box to tick; it's the difference between backing a lab experiment and backing a business. Pair thorough commercial diligence with the right leadership; sometimes that means a fractional chief commercial officer, and the odds shift meaningfully in your favor.
If you're evaluating a life sciences opportunity, Thaver's team has done this before and can walk through what your diligence process might be missing.